Summary. An ELISA was developed for the detection of IgG antibodies to StaphyZococcus uureus collagen binding protein (CnBP) in 95 patients with S. aureus endocarditis, complicated septicaemia with bone and joint involvement or uncomplicated septicaemia and in 95 control patients. Sixty percent of S. aureus-infected patients showed a positive peak anti-CnBP antibody level or a significant rise in titre, or both, during infection, but patients with S . aureus endocarditis or complicated septicaemia could not be differentiated from those with uncomplicated S. aureus septicaemia. The collagen binding capacity of S. aureus strains from 82 of the 95 patients was investigated in a particle agglutination assay and a 1251-labelled assay. All strains bound collagen in the particle agglutination assay as did 68 YO in the '"I-labelled assay, but there was no correlation between collagen binding of the patient strain and endocarditis, joint or skeletal involvement. An anti-CnBP antibody response was seen in 16 patients infected with a S. aureus strain negative for collagen binding in vitro, indicating in-vivo expression of CnBP.
Introduction
Specific attachment by various pathogens to extracellular matrix (ECM) proteins are important steps in early tissue colonisation.' Staphjfococcus aureus binds to several ECM proteins such as fibronectin,2 fibrinogen," heparan sulphate,' vitronectin,' thrombospondin' and various collagens.'.* S. aureus is a common pathogen in bone and joint infection as well as in infective endocarditis,' and collagen type I is a major component of bone, cartilage and endocardium.'* Recent animal studies have suggested that the collagen binding properties of S. aureus strains are correlated with the development of septic arthritis'l A 135-kDa collagen binding protein (CnBP) from S. uzireiis Cowan 1 has been purified, characterised and shown to be highly immunogenic in rabbits,12 and the gene for this protein has been sequenced and c10ned.l~ In the present studies an ELISA was developed with CnBP as antigen to determine the diagnostic value of IgG antibodies to CnBP in patients with S. aureus septicaemia with and without endocarditis or bone and joint involvement and in control patients. The collagen binding capacity of S . aureus strains isolated 
Serum samples
Sera were collected at the Departments of Infectious Diseases, University Hospital of Lund and Orebro Medical Centre Hospital, and stored in divided volumes at -20°C. Acute sera were drawn within 10 days and convalescent sera 11-30 days after onset of infection (usually onset of fever).
Two hundred and twenty-nine sera were analysed from 95 patients with S. aureus septicaemia; in 17 patients only convalescent sera were available. Eighty serum samples were analysed from 40 patients with non-S. aureus endocarditis or septicaemia and from three patients only convalescent sera were available. In the febrile non-septicaemic control group paired sera were available from all 55 patients.
CnBP-ELISA
Purified CnBP was dissolved in phosphate-buffered saline (PBS, pH 7.2) to a concentration of 0-5 pg/ml. Wells of microtitration plates (Maxisorb Nunc, Roskilde, Denmark) were coated with 100 pl of the antigen solution. Plates were incubated at 37°C for 1 h and washed. Patients' sera were diluted 1 in 2000 in PBS with Tween-20 0.05 %, and 100 pl were incubated in each well for 1 h at 37°C. After another washing, 1 0 0~1 of rabbit anti-human IgG diluted 1 in 2000 in PBS-Tween 0.05% were added to each well. Plates were incubated for 1 h on a shaker at room temperature. Finally, plates were washed, incubated with p-nitrophenyl phosphate for 30 min and then read at 405 nm on a spectrophotometer (Multiskan Plus, Labsystems, Helsinki, Finland). Results were related to a positive control and expressed as the ELISA index.
Bacterial strains
S. aureus septicaemia strains were grown in blood culture bottles, isolated on blood agar plates and stored in calf serum at -20°C until use. Seventeen S. aureus strains were available from 18 patients with probable endocarditis, 19 of 21 strains from patients with possible S. aureus endocarditis, 23 of 26 strains from patients with complicated and 23 of 27 strains from patients with uncomplicated S. aureus septicaemia, respectively. No strains were available from patients with definite endocarditis.
Collagen binding assays
Particle agglutination assay. A previously described particle agglutination assay (PAA)15 was used to screen collagen binding properties of 82 S. aureus strains. The strains were cultured on blood agar which has been shown to increase collagen binding capacity as compared to other media.15 S. aureus strain Cowan 1 served as a positive control. Strains were suspended in 0-02 M potassium phosphate buffer (pH 6.8) to c. lo1* cells/ml. Latex beads were coated with bovine collagen. One drop of bacterial suspension was mixed with coated latex beads in 0.17 M glycine NaOH buffer (pH 6.8) on a glass slide. Strains were tested for autoaggregation by mixing them with uncoated latex beads.
Results were scored from 3 + when strains agglutinated within 30 s, 2 + within 1 min, 1 + within 2 min to negative (-) when there was no agglutination within 2 min.16 "I-collagen binding assay. Bovine collagen was labelled with lZ51 according to a modified Chloramine-T method with 1odobeadsK.lG S. aureus strains were cultured for 24 h at 37°C on blood agar, harvested, washed and resuspended in PBS to c. 5 x lo9 cfu/ml. 125J-collagen was diluted to c. 0.3 x lo4 cpm/50 pl in PBS with BSA 1' 10 and added to 100 pl of bacterial suspension. After mixing, tubes were incubated for 1 h at room temperature. The binding reaction was stopped by adding 2 ml of PBS + Tween-20 0.1 YO v/v.
After centrifugation at 3000 rpm for 15 min the supernate was aspirated and the radioactivity of the pellet was measured in a 1260 Multigamma counter (LKB-Wallac, Turku, Finland). Results were expressed as percentage radioactivity of total amount of 1251-co11agen added. S . aureus Cowan 1 served as a positive control.
Statimkui unuiysi.s
For evaluation of the reproducibility of an assay, the analytical error was calculated. The inter-assay error was expressed as the standard deviation of the single determination s = & v(Sd2/2n) where Sd' equals the squared sum of differences within pairs and n equals the number of pairs. Since the absolute differences within paired observations in the CnBPELlSA rose with higher optical density values, the standard deviations of the single determinations in this assay were calculated as percentage values. The x2 test was used to compare differences in anti-CnBP levels in various patient groups and collagen binding capacity in strains from patients with S. aureus endocarditis, complicated and uncomplicated septicaemia.
antibody level. The analytical error of the method was 21 Yo and a significant rise in titre between acute and convalescent sera was defined as > 50% increase of ELISA index. Positive peak anti-CnBP titres or a significant titre rise, or both, were found in 43 (63 YO) of 68 S. aureus infected patients with endocarditis or bone and joint infection as compared to 14 (52%) of 27 patients with uncomplicated S. aureus septicaemia (table 11) . This difference was not significant (p > 0.05). No patients with non-S. aureus endocarditis was positive, but two patients with P . aeruginosa and one with Str. pneumoniae septicaemia showed significant rises in titre. Thus, the specificity for diagnosing S . clureus endocarditis or septicaemia, or both, was 92% (37 of 40) in the present studies.
Six S. aureus strains auto-aggregated in the PAA and all the remaining 76 strains bound collagen ( There was no significant correlation (p > 0.05) between the development of endocarditis or joint and skeletal infection and the collagen binding capacity of corresponding strains of S. aureus with either collagen binding assay (table 111) . Fifty-one strains were available from patients seropositive for anti-CnBP, among which 16 (31 YO) were found negative in the lZ5I-collagen binding assay. The patients infected with these 16 strains developed positive peak anti-CnBP antibody level (n = 8), rise in titre (3) or both (5).
Discussion Results
The upper normal anti-CnBP IgG level was defined as the mean value of the febrile control group + 2 SD.
This gave an upper normal ELISA index of 0.712. As shown in fig. 1 and table 11 , peak anti-CnBP IgG levels above cut-off were found in 12 (57%) of 21 patients with definite or probable S. aureus endocarditis, 9 (43%) of 21 patients with possible S. aureus endocarditis, 9 (35 O/O) of 26 patients with S. aureus complicated septicaemia, 8 (30 YO) of 27 patients with S. aureus uncomplicated septicaemia and 3 ( 5 % ) of 55 febrile control patients. No patients with non-S. aureus endocarditis or septicaemia showed a positive peak Many serological assays with various S. aureus antigens have been published over the last decade with the purpose of finding an assay or a combination of assays that could distinguish patients with complicated septicaemia, including endocarditis and deep-seated tissue infections, from those with uncomplicated septi~aemia.''-~l No single assay has so far proved to be adequate for this differential diagnosis, but combinations of assays have in some cases reached acceptable predictive values. In the present studies an ELISA was developed to determine the IgG antibody response towards S . atireus CnBP. Detectable antibodies to CnBP were found in all S. aureus-infected patients as well as in controls ( fig. l) , which has also been reported with serological assays with various S. aureus antigen~.l'-~l Cross-reacting antibodies in non-S. aureus endocarditis or septicaemia were seen in only 3 (8%) of 40 patients, two patients with P. aeruginosa septicaemia and one patient with Str. pneumoniae septicaemia showing a significant rise in titre although not reaching a positive peak antibody level. Thus, this assay seems to be highly specific for S. aureus infection, and contrary to, for example, assays with S. aureus teichoic acid, peptidoglycan, crude S. aureus antigen, whole S. aureus cells and a -t~X i n ,~&~~* 24 no cross-reacting antibodies were seen in patients with endocarditis or septicaemia due to a-streptococci, enterococci or coagulase-negative staphylococci. This could be due to the use of a highly purified protein specific for S. uureus. The overall sensitivity in diagnosing S. aureus endocarditis or septicaemia was 60 YO (57 of 95) (table II), which is similar to the results of several other serological assay^^^-'^. 21 and indicates that CnBP is highly immunogenic. It was assumed that patients with S. aureus endocarditis or complicated septicaemia would show increased anti-CnBP levels based on the expected increase in CnBP expression when S. aureus adheres to the collagen of endocardium, bone and cartilage. However, there was no significant difference in antibody levels among these patients as compared to those with S. aureus uncomplicated septicaemia (p > 0-OS), and thus the anti-CnBP ELISA could not be used as a single assay to differentiate between such patient groups.
In previous studies a correlation between S . aureus endocarditis, arthritis and osteomyelitis and high collagen binding capacity of corresponding S. aureus strains has been suggested. In an animal model, intravenous challenge of S . aureus strain Phillips expressing CnBP caused septic arthritis in all of 10 mice, as compared to 5 of 10 mice challenged with a mutant strain not expressing CnBP.l' With lZ5I-collagen, Holderbaum et a1. 26 1 3 of 4 1) . The authors did not give diagnostic criteria for their patients with endocarditis, joint or skeletal infection and their septicaemic patients without signs of metastatic infections all had infected intravenous catheters. In the present studies, a similar 1251-co11agen binding assay was used but no difference in the collagen binding capacity of S. aureus strains from patients with or without endocarditis or bone or joint infection was found (table 111) . One possible reason for this discrepancy could be that S. aureus strains colonising intravenous catheters differ in their collagen binding capacity from other septicaemia strains. However, all strains studied, except for six autoagglutinating strains, were positive in the PAA, and it could be argued that the PAA better reflects in-vivo conditions (collagens do not appear in solution in vivolO). Furthermore, 16 patients infected with S. aureus strains negative in the 1251-co11agen binding assay who had positive anti-CnBP antibody levels (n = S), significant rises in titre (n = 3) or both (n = 5) were found. These results indicate in-vivo expression of CnBP in in-vitro negative strains. It is of interest to note that inconsistencies between antibody response and expression of S. aureus antigen have been reported previously. Rollof et al. found no significant difference in lipase activity between septicaemic strains from 22
